Payment overview · 2025
General Payments
$47.81
3 reported records · 3 companies
Healthcare provider profile · identity verified
Brent Jameson, MD
Allopathic & Osteopathic Physicians|Family Medicine · STROMSBURG, NE · NPI 1750769360
Verified facts
What the public records show
CMS Open Payments records show Brent Jameson, MD received $47.81 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.58 | 36.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.41 | 34.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.82 | 28.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $47.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 356 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 35 |
| Lisinopril | Lisinopril | 208 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 23 |
| Potassium Chloride | Potassium Chloride | 186 | 20 |
| Gabapentin | Gabapentin | 169 | 20 |
| Omeprazole | Omeprazole | 165 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 20 |
| Tramadol Hcl | Tramadol Hcl | 141 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 13 |
| Trazodone Hcl | Trazodone Hcl | 82 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 80 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 79 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 75 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 13 |
| Metformin Hcl | Metformin Hcl | 72 | suppressed |
| Pregabalin | Pregabalin | 69 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 15 |
| Alprazolam | Alprazolam | 63 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 63 | suppressed |
| Simvastatin | Simvastatin | 57 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | suppressed |
| Losartan Potassium | Losartan Potassium | 54 | 14 |
| Eliquis | Apixaban | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Prednisone | Prednisone | 44 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Naproxen | Naproxen | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 17 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Loperamide | Loperamide Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Novolog | Insulin Aspart | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Tresiba | Insulin Degludec | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47.81 · 3 records | Novo Nordisk Inc | AIRSUPRA, JARDIANCE, Ozempic, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error